Somatostatin receptor expression in lung cancer

K. J. O'Byrne, G. Halmos, J. Pinski, K. Groot, K. Szepeshazi, Andrew V Schally, D. N. Carney

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Experimental evidence suggests that somatostatin analogues may have a role to play in the management of lung tumours. We evaluated membrane preparations of nine small cell lung cancer (SCLC) cell lines and of tumour samples from 3 patients with non-small cell lung cancer (NSCLC), 1 patient with an atypical carcinoid and another with a bronchial carcinoid for the presence of specific binding sites for RC-160, a potent growth inhibitory octapeptide analogue of somatostatin. Specific binding was noted on six of nine SCLC lines. Radio-receptor assay on the cell line NCI H 69 showed evidence of two specific binding sites for RC-160, one with high affinity and the other with low affinity. Binding sites were also found on all five tumour samples. Scatchard analysis indicated the presence of a single class of receptors with high affinity in each case. Histological assessment of the resected specimens before binding assay showed them to be comprised of tumour cells and necrotic tissue, stroma and/or inflammatory cells. Therefore, the specific binding of RC-160 may be to tissues other than the tumour cells. In 3 patients, from whom the tumour samples were obtained, radiolabelled somatostatin analogue scintigraphy using [111In] pentetreotide was performed prior to surgery. In all cases, the radiolabel localised the disease. This study demonstrates the presence of specific binding sites for RC-160 in SCLC. Furthermore, the detection of specific binding in vitro and in vivo in NSCLC and intrapulmonary carcinoids demonstrates that these tumours contain cells which express specific binding sites for somatostatin. These results suggest that RC-160 may have a role to play as a therapeutic agent in lung cancer.

Original languageEnglish
Pages (from-to)1682-1687
Number of pages6
JournalEuropean Journal of Cancer
Volume30
Issue number11
DOIs
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Somatostatin Receptors
Lung Neoplasms
Somatostatin
Binding Sites
Small Cell Lung Carcinoma
Carcinoid Tumor
Neoplasms
Non-Small Cell Lung Carcinoma
Tumor Cell Line
Radio
Radionuclide Imaging
vapreotide
Cell Line
Lung
Membranes
Growth

Keywords

  • lung cancer
  • RC-160
  • receptor
  • somatostatin
  • [In] pentetreotide

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

O'Byrne, K. J., Halmos, G., Pinski, J., Groot, K., Szepeshazi, K., Schally, A. V., & Carney, D. N. (1994). Somatostatin receptor expression in lung cancer. European Journal of Cancer, 30(11), 1682-1687. https://doi.org/10.1016/0959-8049(94)00351-5

Somatostatin receptor expression in lung cancer. / O'Byrne, K. J.; Halmos, G.; Pinski, J.; Groot, K.; Szepeshazi, K.; Schally, Andrew V; Carney, D. N.

In: European Journal of Cancer, Vol. 30, No. 11, 01.01.1994, p. 1682-1687.

Research output: Contribution to journalArticle

O'Byrne, KJ, Halmos, G, Pinski, J, Groot, K, Szepeshazi, K, Schally, AV & Carney, DN 1994, 'Somatostatin receptor expression in lung cancer', European Journal of Cancer, vol. 30, no. 11, pp. 1682-1687. https://doi.org/10.1016/0959-8049(94)00351-5
O'Byrne KJ, Halmos G, Pinski J, Groot K, Szepeshazi K, Schally AV et al. Somatostatin receptor expression in lung cancer. European Journal of Cancer. 1994 Jan 1;30(11):1682-1687. https://doi.org/10.1016/0959-8049(94)00351-5
O'Byrne, K. J. ; Halmos, G. ; Pinski, J. ; Groot, K. ; Szepeshazi, K. ; Schally, Andrew V ; Carney, D. N. / Somatostatin receptor expression in lung cancer. In: European Journal of Cancer. 1994 ; Vol. 30, No. 11. pp. 1682-1687.
@article{1e1b899db19049ff9954e7e99ceee3eb,
title = "Somatostatin receptor expression in lung cancer",
abstract = "Experimental evidence suggests that somatostatin analogues may have a role to play in the management of lung tumours. We evaluated membrane preparations of nine small cell lung cancer (SCLC) cell lines and of tumour samples from 3 patients with non-small cell lung cancer (NSCLC), 1 patient with an atypical carcinoid and another with a bronchial carcinoid for the presence of specific binding sites for RC-160, a potent growth inhibitory octapeptide analogue of somatostatin. Specific binding was noted on six of nine SCLC lines. Radio-receptor assay on the cell line NCI H 69 showed evidence of two specific binding sites for RC-160, one with high affinity and the other with low affinity. Binding sites were also found on all five tumour samples. Scatchard analysis indicated the presence of a single class of receptors with high affinity in each case. Histological assessment of the resected specimens before binding assay showed them to be comprised of tumour cells and necrotic tissue, stroma and/or inflammatory cells. Therefore, the specific binding of RC-160 may be to tissues other than the tumour cells. In 3 patients, from whom the tumour samples were obtained, radiolabelled somatostatin analogue scintigraphy using [111In] pentetreotide was performed prior to surgery. In all cases, the radiolabel localised the disease. This study demonstrates the presence of specific binding sites for RC-160 in SCLC. Furthermore, the detection of specific binding in vitro and in vivo in NSCLC and intrapulmonary carcinoids demonstrates that these tumours contain cells which express specific binding sites for somatostatin. These results suggest that RC-160 may have a role to play as a therapeutic agent in lung cancer.",
keywords = "lung cancer, RC-160, receptor, somatostatin, [In] pentetreotide",
author = "O'Byrne, {K. J.} and G. Halmos and J. Pinski and K. Groot and K. Szepeshazi and Schally, {Andrew V} and Carney, {D. N.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1016/0959-8049(94)00351-5",
language = "English",
volume = "30",
pages = "1682--1687",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Somatostatin receptor expression in lung cancer

AU - O'Byrne, K. J.

AU - Halmos, G.

AU - Pinski, J.

AU - Groot, K.

AU - Szepeshazi, K.

AU - Schally, Andrew V

AU - Carney, D. N.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Experimental evidence suggests that somatostatin analogues may have a role to play in the management of lung tumours. We evaluated membrane preparations of nine small cell lung cancer (SCLC) cell lines and of tumour samples from 3 patients with non-small cell lung cancer (NSCLC), 1 patient with an atypical carcinoid and another with a bronchial carcinoid for the presence of specific binding sites for RC-160, a potent growth inhibitory octapeptide analogue of somatostatin. Specific binding was noted on six of nine SCLC lines. Radio-receptor assay on the cell line NCI H 69 showed evidence of two specific binding sites for RC-160, one with high affinity and the other with low affinity. Binding sites were also found on all five tumour samples. Scatchard analysis indicated the presence of a single class of receptors with high affinity in each case. Histological assessment of the resected specimens before binding assay showed them to be comprised of tumour cells and necrotic tissue, stroma and/or inflammatory cells. Therefore, the specific binding of RC-160 may be to tissues other than the tumour cells. In 3 patients, from whom the tumour samples were obtained, radiolabelled somatostatin analogue scintigraphy using [111In] pentetreotide was performed prior to surgery. In all cases, the radiolabel localised the disease. This study demonstrates the presence of specific binding sites for RC-160 in SCLC. Furthermore, the detection of specific binding in vitro and in vivo in NSCLC and intrapulmonary carcinoids demonstrates that these tumours contain cells which express specific binding sites for somatostatin. These results suggest that RC-160 may have a role to play as a therapeutic agent in lung cancer.

AB - Experimental evidence suggests that somatostatin analogues may have a role to play in the management of lung tumours. We evaluated membrane preparations of nine small cell lung cancer (SCLC) cell lines and of tumour samples from 3 patients with non-small cell lung cancer (NSCLC), 1 patient with an atypical carcinoid and another with a bronchial carcinoid for the presence of specific binding sites for RC-160, a potent growth inhibitory octapeptide analogue of somatostatin. Specific binding was noted on six of nine SCLC lines. Radio-receptor assay on the cell line NCI H 69 showed evidence of two specific binding sites for RC-160, one with high affinity and the other with low affinity. Binding sites were also found on all five tumour samples. Scatchard analysis indicated the presence of a single class of receptors with high affinity in each case. Histological assessment of the resected specimens before binding assay showed them to be comprised of tumour cells and necrotic tissue, stroma and/or inflammatory cells. Therefore, the specific binding of RC-160 may be to tissues other than the tumour cells. In 3 patients, from whom the tumour samples were obtained, radiolabelled somatostatin analogue scintigraphy using [111In] pentetreotide was performed prior to surgery. In all cases, the radiolabel localised the disease. This study demonstrates the presence of specific binding sites for RC-160 in SCLC. Furthermore, the detection of specific binding in vitro and in vivo in NSCLC and intrapulmonary carcinoids demonstrates that these tumours contain cells which express specific binding sites for somatostatin. These results suggest that RC-160 may have a role to play as a therapeutic agent in lung cancer.

KW - lung cancer

KW - RC-160

KW - receptor

KW - somatostatin

KW - [In] pentetreotide

UR - http://www.scopus.com/inward/record.url?scp=0028034462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028034462&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(94)00351-5

DO - 10.1016/0959-8049(94)00351-5

M3 - Article

C2 - 7833144

AN - SCOPUS:0028034462

VL - 30

SP - 1682

EP - 1687

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 11

ER -